NCT00289926View on ClinicalTrials.gov

Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Quality of LifeMenopausal SyndromeLibido Disorder
Interventions
DRUG

dehydroepiandrosterone

dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule

DRUG

placebo

Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule

Trial Locations (1)

3004

Women's Health Research Program, Monash University, The Alfred Hospital, Melbourne

All Listed Sponsors
lead

Monash University

OTHER

NCT00289926 - Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms | Biotech Hunter | Biotech Hunter